MetaCap

AgomAb Therapeutics NV (AGMB) vs Ocugen (OCGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $260.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-62.80%OCGN-42.26%
+94%+12%-70%
Feb 6, 20261 yearNov 20, 2026
AGMB-62.80%OCGN-42.26%
+94%+12%-70%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus OCGN key metrics
MetricAGMBOCGN
Share price$5.45$0.7679
Market cap$268.40M$260.55M
1-day change-3.02%+4.79%
YTD return—-43.12%
1-year return—-33.80%
5-year return—-88.09%
EPS (TTM)$-2.08$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.41M
Revenue growth (YoY)—+8.83%
Net income (latest FY)—$-67.85M
Operating margin—-1425.70%
Net margin—-1537.41%
52-week high$17.82$2.73
52-week low$5.39$0.691
Distance from 52-week high-69.42%-71.82%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+591.19%+1484.84%
Average volume208.99K7.34M
Shares outstanding49.25M339.31M
Employees62116
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

AGMB vs OCGN FAQ

Which is bigger, AgomAb Therapeutics NV or Ocugen?

AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $260.55M for Ocugen (OCGN).

Are AgomAb Therapeutics NV and Ocugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons